636,136 Shares in BioAtla, Inc. (NASDAQ:BCAB) Acquired by AQR Capital Management LLC

AQR Capital Management LLC acquired a new stake in BioAtla, Inc. (NASDAQ:BCAB) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 636,136 shares of the company’s stock, valued at approximately $872,000. AQR Capital Management LLC owned approximately 1.32% of BioAtla as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Ground Swell Capital LLC acquired a new stake in shares of BioAtla in the second quarter valued at about $33,000. Valmark Advisers Inc. purchased a new position in BioAtla in the 2nd quarter worth approximately $34,000. Rinkey Investments purchased a new position in BioAtla in the 2nd quarter worth approximately $35,000. Price T Rowe Associates Inc. MD acquired a new position in shares of BioAtla during the 1st quarter worth approximately $45,000. Finally, American Century Companies Inc. grew its position in shares of BioAtla by 36.1% in the second quarter. American Century Companies Inc. now owns 43,391 shares of the company’s stock valued at $59,000 after purchasing an additional 11,503 shares in the last quarter. Institutional investors and hedge funds own 77.23% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, JMP Securities reiterated a “market outperform” rating and set a $5.00 price objective on shares of BioAtla in a research report on Monday, September 16th.

BioAtla Trading Up 7.3 %

Shares of BCAB opened at $2.07 on Friday. BioAtla, Inc. has a 12-month low of $1.14 and a 12-month high of $4.02. The firm has a market capitalization of $100.06 million, a P/E ratio of -0.95 and a beta of 1.06. The firm has a 50-day moving average price of $1.78 and a 200 day moving average price of $2.05.

BioAtla (NASDAQ:BCAB) last posted its earnings results on Thursday, August 8th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.01. During the same quarter last year, the business earned ($0.75) earnings per share. Equities research analysts predict that BioAtla, Inc. will post -1.52 earnings per share for the current fiscal year.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.